Colorectal Cancer

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    BRAF Mutation 5–8 Vemurafenib (BRAF inhibitor):
    • Phase 2, with cetuximab (EGFR inhibitor) and irinotecan: PFS 4.3 vs. 2.0 mo (HR 0.48), PR 16% vs. 4%, DCR (PR + SD) 67% vs. 22% favoring the arm with vemurafenib (1)
    Dabrafenib (BRAF inhibitor):
    • Phase 2, with trametinib and panitumumab: RR and SD of 10% and 80% for dabrafenib + panitumumab, 0% and 53% for trametinib + panitumumab, and 18% and 67% for dabrafenib + trametinib + panitumumab (2)
    Encorafenib (BRAF inhibition):
    Other topics in Targets by Organ Site